Get the Stockscreener App
42.11
5.17%
2.07
Cogent Biosciences Inc stock is traded at $42.11, with a volume of 2.83M.
It is up +5.17% in the last 24 hours and up +19.43% over the past month.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
See More
Previous Close:
$40.04
Open:
$39.66
24h Volume:
2.83M
Relative Volume:
0.93
Market Cap:
$6.46B
Revenue:
-
Net Income/Loss:
$-284.08M
P/E Ratio:
-17.38
EPS:
-2.4234
Net Cash Flow:
$-234.65M
1W Performance:
+8.61%
1M Performance:
+19.43%
6M Performance:
+483.24%
1Y Performance:
+404.92%
1-Day Range:
$39.26
$42.24
1-Week Range:
$37.86
$43.73
52-Week Range:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Name
Cogent Biosciences Inc
Sector
Industry
Phone
617-945-5576
Address
275 WYMAN STREET, WALTHAM
Compare COGT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
42.11 | 6.15B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-10-25 | Upgrade | Stifel | Hold → Buy |
| Nov-10-25 | Upgrade | Wedbush | Neutral → Outperform |
| Oct-16-25 | Initiated | Stifel | Hold |
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-11-24 | Downgrade | Needham | Buy → Hold |
| Feb-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-08-24 | Initiated | Citigroup | Buy |
| Dec-11-23 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-08-23 | Initiated | JP Morgan | Overweight |
| Apr-28-23 | Initiated | Robert W. Baird | Outperform |
| Mar-27-23 | Resumed | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Jun-28-22 | Initiated | Guggenheim | Buy |
| Oct-11-21 | Initiated | H.C. Wainwright | Buy |
| Jun-09-21 | Resumed | Jefferies | Buy |
| Dec-23-20 | Initiated | Piper Sandler | Overweight |
| Oct-14-20 | Initiated | Ladenburg Thalmann | Buy |
View All
Cogent Biosciences Inc Stock (COGT) Latest News
Frazier Life Sciences Management L.P. Grows Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences prices equity offering and 1.625% convertible senior notes - MSN
Cogent Biosciences’ Stock Climbs with Landmark Clinical Trial Results - StocksToTrade
The Technical Signals Behind (COGT) That Institutions Follow - news.stocktradersdaily.com
Cogent Biosciences Stock Soars on Positive Trial Results - timothysykes.com
Birchview Capital LP Buys New Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
COGT Boom: Is It Time to Cash In? - StocksToTrade
Redmile Group LLC Sells 1,767,986 Shares of Cogent Biosciences, Inc. $COGT - MarketBeat
Will Rising Interest Rates Hurt Piramal Pharma Limiteds Profit MarginsHead and Shoulders Patterns & Access Free Tools and Start Investing - earlytimes.in
Cogent Biosciences (COGT): Valuation Check After Positive APEX Part 2 Trial Results for Bezuclastinib - Sahm
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - Investing News Network
Cogent Biosciences stock hits all-time high at 43.07 USD By Investing.com - Investing.com Canada
Cogent Biosciences Presents Positive Clinical Trial Results - TradingView — Track All Markets
Cogent Biosciences (NASDAQ:COGT) Given "Hold" Rating at Needham & Company LLC - MarketBeat
Cogent Biosciences (COGT) Receives 'Hold' Rating from Needham | - GuruFocus
Cogent Biosciences (NASDAQ:COGT) Reaches New 1-Year HighHere's What Happened - MarketBeat
Wedbush Adjusts Cogent Biosciences Price Target to $55 From $38, Maintains Outperform Rating - marketscreener.com
Cogent Biosciences Says Bezuclastinib Showed 'Rapid and Deep Clinical Benefit' in Advanced Systemic Mastocytosis Trial - marketscreener.com
Cogent Biosciences stock hits all-time high at 43.07 USD - Investing.com
Cogent Biosciences : COGT ASH 2025 Webcast FINAL - marketscreener.com
Cogent Biosciences (COGT) Reports Positive Results from APEX Par - GuruFocus
Cogent Biosciences announces positive top-line results of apex trial of bezuclastinib in patients with advanced systemic mastocytosis - marketscreener.com
Cogent Biosciences Announces Positive Top-Line Results Of APEX Trial Of Bezuclastinib In Patients With Advanced Systemic Mastocytosis - TradingView — Track All Markets
Cogent Biosciences, Inc. Announces Positive Top-Line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis - marketscreener.com
Schroder Investment Management Group Invests $896,000 in Cogent Biosciences, Inc. $COGT - MarketBeat
Bollard Group LLC Buys New Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences' (COGT) Bezuclastinib Shows Promising Results in Clinical Trial - GuruFocus
Cogent Biosciences, Inc. $COGT Shares Purchased by Kennedy Capital Management LLC - MarketBeat
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis at the 67th Annual Meeting of the American Society of Hematology - Investing News Network
Cogent Biosciences Reports Positive Results for Bezuclastinib in Nonadvanced Systemic Mastocytosis at SUMMIT Trial, Prepares for NDA Submission - Quiver Quantitative
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) - The Manila Times
Tema Etfs LLC Has $845,000 Holdings in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Cogent Biosciences, Inc. $COGT is Saturn V Capital Management LP's 5th Largest Position - MarketBeat
Cogent Biosciences, Inc. (NASDAQ:COGT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is Cogent Biosciences Inc a good long term investmentREITs Market Trends & Free Exceptional ROI Methods - earlytimes.in
Can Cogent Biosciences Inc. stock deliver consistent earnings growthJuly 2025 Technicals & High Conviction Buy Zone Alerts - Newser
Stock Traders Buy Large Volume of Cogent Biosciences Call Options (NASDAQ:COGT) - MarketBeat
XTX Topco Ltd Has $836,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Has $94,000 Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Price Target Increased by 93.94% to 43.52 - MSN
Geode Capital Management LLC Raises Stake in Cogent Biosciences, Inc. $COGT - MarketBeat
F m Investments LLC Takes Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Ensign Peak Advisors Inc Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences stock hits 52-week high at 40.76 USD By Investing.com - Investing.com Nigeria
Cogent Biosciences stock hits 52-week high at 40.76 USD - Investing.com
A Look at Cogent Biosciences (COGT) Valuation Following Positive Phase 3 Trial Results - Sahm
Cogent Biosciences (NASDAQ:COGT) Reaches New 52-Week HighWhat's Next? - MarketBeat
Biotech Star Cogent Rides High On Breakthrough Trial Hopes - Finimize
Cogent Biosciences Announces $230 Million Convertible Senior Notes Offering - Global Legal Chronicle
Cogent Biosciences Inc Stock (COGT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):